A revolutionary therapeutic
to enhance the body’s natural immune response.
A revolutionary therapeutic
to enhance the body’s natural immune response.
0%
0%
0%
0%
0%
0%
WordPress
0%
WordPress
0%
WordPress
0%
WordPress
0%
WordPress
0%
WordPress
0%
WordPress
0%
WordPress
0%
WordPress
0%
Unlike existing treatments, which suppress the immune response, SP16 enhances the body’s innate mechanism for resolving inflammation. Our therapeutic restores immune balance by targeting a receptor that plays a key role in mitigating inflammation. This platform technology has the potential to treat a wide range of inflammatory diseases.
Eosinophilic Esophagitis (EoE) results from allergen-induced inflammation of the throat. It is an orphan indication with limited treatment options. In the U.S., an estimated 150,000 patients (largely children) suffer from this disorder.
In preclinical models, SP16 was shown to:
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare disorder characterized by inflammation of the nerves, leading to chronic pain, weakness, numbness, and loss of function in the affected area(s). Current treatments have negative side effects and are not ideal for long-term use. The CIPD market value is anticipated to reach 3.9 billion USD by 2023.1
In preclinical models, SP16 was shown to:
Pemphigus vulgaris and pemphigoid skin diseases are rare, life-threatening autoimmune disorders characterized by painful blistering of the body’s mucous membranes, including those in the nose, mouth, and throat. The current standards of care often fail to control pain and cause adverse effects with long-term use. By 2026, the inflammatory skin disease treatment market is estimated at 23 billion USD.1
Well-aligned with currently understood driving forces of the disease, SP16 has the potential to:
Acute myocardial infarction (AMI), also known as a heart attack, invokes an intense inflammatory response which increases heart damage and prolongs recovery. High levels of cardiac inflammation are associated with severe complications, including heart failure. The heart failure market is expected to grow to $22.1 billion by 2028 at a compound annual growth rate of 19.5%.1
In a Phase 2a clinical trial, a single dose of SP16 was shown to:
Acute Lung Injury (ALI) and acute respiratory distress syndrome (ARDS) are life-threatening respiratory disorders associated with an uncontrolled inflammatory response. Severe respiratory inflammation is a critical hallmark of COVID-19 infection.
In preclinical models, SP16 was shown to:
Clinical trials to determine the safety and ability of SP16 to lower inflammation in hospitalized patients with COVID-19 are currently underway.
Acute Kidney Injury (AKI) is defined as loss of kidney function and is a large risk factor of heart surgery. Cardiac-surgery-associated AKI is further associated with other adverse outcomes, including chronic kidney disease (CKD) and death. The AKI market is projected to reach US $31.6 billion by 2025. 1
In preclinical models, SP16 was shown to:
Atopic Dermatitis (AD), also known as eczema, is the most prevalent inflammatory skin disease in humans. Although mild cases can be managed by current treatment options, advanced AD is only treated by medications with severe side effects.
In preclinical models, SP16 was shown to:
Alopecia Areata (AA) is an autoimmune disease that targets the body’s hair follicles, resulting in hair loss. There are currently no FDA-approved treatments for moderate to severe disease states. The market size for AA treatment is estimated at approximately $1.7 billion USD by 2028.1
Well-aligned with currently understood driving forces of the disease, SP16 has the potential to:
References
1 Wylezinski, L. S., Gray, J. D., Polk, J. B., Harmata, A. J., & Spurlock, C. F. (2019). Illuminating an invisible epidemic: a systemic review of the clinical and economic benefits of early diagnosis and treatment in inflammatory disease and related syndromes. Journal of Clinical Medicine, 8(4), 493.
2Global data. Retrieved from https://www.globaldata.com.
